Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis: results from the RECOVER trial
Paul G. McNally, Karen Lester, Rachel Cregan, B. Elnazir et autres
kn, ie, ca, nl, gb, us (code pays fourni par la source)